drugset
drugset / Trial / NCT04965220

HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors

NCT04965220 ↗

Phase 1 Unknown 220 enrolled Shanghai Henlius Biotech
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and initial efficacy of HLX208 (BRAF V600E inhibitor) in combination with trametinib in patients with advanced solid tumors

Timeline

Start
2022-01-05
Primary completion
2024-06-30
Completion
2025-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HLX208 Unknown — Oral

Indications

cancer